ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Change in Effectiveness and Safety Parameters After Initiation of SGLT2 Inhibitors for Post-Transplant Diabetes Mellitus: A Real-World Observational Study.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPost-transplant diabetes mellitus (PTDM) is frequent and associated with increased cardiovascular and renal risk. Evidence regarding the long-term effectiveness and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in PTDM remains limited.
methodsWe conducted a single-center retrospective observational study including 86 solid organ transplant recipients with diabetes treated with SGLT2 inhibitors between January 2017 and July 2025. Seventy patients who received treatment for ≥ 6 months were included in efficacy analyses. The primary endpoint was change in HbA1c over time. Secondary endpoints included changes in body weight, systolic blood pressure (SBP), estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), treatment modifications, and safety outcomes.
resultsParticipants (72/86 men; mean age 65.9 years) were followed for a mean of 1.6 ± 1.4 years. A significant HbA1c reduction was observed only between years 2 and 3 (- 0.6% vs baseline), while overall longitudinal variation was not statistically significant. Body weight significantly decreased over time (p = 0.007), with a maximum reduction of - 5.5 kg. No significant changes were observed in SBP or uACR. A progressive decline in eGFR was detected during follow-up (p < 0.001), but only four patients had a ≥ 50% eGFR decline. Urogenital infections occurred in 7% of patients (5.1 cases/100 person-years), leading to treatment discontinuation in 4.6%. Overall discontinuation rate was 19.8%.
conclusionIn this real-world descriptive study on PTDM, initiation of an SGLT2 inhibitor was followed by sustained weight reduction and delayed glycemic improvement, with an acceptable safety profile. The observed long-term renal decline warrants further investigation in controlled prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.